	US 12,109,255 B2
	Choline acetyltransferase as a therapy for hypertension
Kevin J. Tracey, Old Greenwich, CT (US); Sangeeta S. Chavan, Syosset, NY (US); Andrew Stiegler, Deer Park, NY (US); and Jian Hua Li, New York, NY (US)
Assigned to THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH, Manhasset, NY (US)
Appl. No. 17/299,392
Filed by THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH, Manhasset, NY (US)
PCT Filed Dec. 11, 2019, PCT No. PCT/US2019/065653 § 371(c)(1), (2) Date Jun. 3, 2021, PCT Pub. No. WO2020/123611, PCT Pub. Date Jun. 18, 2020.
Claims priority of provisional application 62/778,355, filed on Dec. 12, 2018.
Prior Publication US 2022/0054599 A1, Feb. 24, 2022
Int. Cl. A61K 38/45 (2006.01); A61K 47/60 (2017.01); A61P 9/12 (2006.01)

CPC A61K 38/45 (2013.01) [A61K 47/60 (2017.08); A61P 9/12 (2018.01); C12Y 203/01006 (2013.01)]

18 Claims

1. A method of reducing systemic hypertension in a subject in need thereof comprising administering to the subject a choline acetyltransferase (ChAT) protein or a ChAT protein conjugated to polyethylene glycol (PEG) in an amount and manner effective to reduce systemic hypertension in a subject,

wherein the subject is an adult human 18 years or older who prior to administration of ChAT protein or PEGylated ChAT protein had a resting systolic blood pressure at or above 130 mmHg and/or a diastolic blood pressure at or above 80 mmHg, and

wherein administration of ChAT protein or PEGylated ChAT protein is effective to reduce systolic blood pressure by 10-40 mmHg.